Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and…

Bristol-Myers Squibb’s Opdivo® (nivolumab) + Low-Dose Yervoy® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and…

July 11, 2018 Bristol-Myers Squibb’s Opdivo ® (nivolumab) + Low-Dose Yervoy ® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan In the CheckMate -142 trial, Opdivo +

Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018

Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018

June 2, 2018 Data from the Phase 1 dose-escalation and early data from the Phase 2 dose expansion phase of the ongoing PIVOT study highlighted as an oral presentation. CHICAGO, June 2, 2018 /PRNewswire/ — Nektar Therapeutics (Nasdaq: NKTR) and Bristol-Myers Squibb (NYSE: BMY)

U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma

U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma

June 01, 2018 FDA action removes partial hold on CheckMate -602, the last of holds previously placed on three Opdivo-based combination trials in relapsed or refractory multiple myeloma PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and

European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)

If approved, Opdivo plus Yervoy would be the first I-O/I-O combination in the EU for first-line metastatic NSCLC patients with tumor mutational burden ≥10 mutations/megabase Positive results from CheckMate -227, a pivotal Phase 3 study comparing Opdivo plus low-dose Yervoyversus chemotherapy in this patient population, serves as

Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement

Strengthens Real-World Data Capabilities in Oncology Research at BMS WEDNESDAY, MAY 2, 2018 8:30 AM EDT NEW YORK–(BUSINESS WIRE)–Bristol-Myers Squibb (NYSE:BMY) and Flatiron Health, a market leader in oncology-specific electronic health record software and the curation of regulatory-grade real-world data

European Commission Approves Bristol-Myers Squibb’s Opdivo (nivolumab) Four-Week Dosing Schedule for Advanced Melanoma and Previously Treated Renal Cell Carcinoma

First and only PD-1 inhibitor approved in the EU to offer every four-week dosing Opdivo also now approved for two-week flat dose option with 30-minute infusions across all approved monotherapy indications in the EU  WEDNESDAY, APRIL 25, 2018 4:20 PM EDT

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients with Small Cell Lung Cancer and Grants Priority Review

WEDNESDAY, APRIL 18, 2018 4:15 PM EDT PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application for Opdivo (nivolumab) to treat patients with small cell lung cancer (SCLC)